Antengene Corporation Limited stock analysis
Want to see HK:6996 full AI Analyst Report?
Antengene Corporation Limited (6996) Stock Price & Analysis
6996 Stock Chart & Stats
- Day’s Range
- HKD 2.53 - HKD 2.90
- 52-Week Range
- HKD 2.53 - HKD 6.28
- Previous Close
- HKD 2.71
- Volume
- N/A
- Average Volume (3M)
- 737.78K
- Market Cap
- HKD 1.67B
- Enterprise Value
- HKD 1.68B
- Total Cash (Recent Filing)
- HKD 764.90M
- Total Debt (Recent Filing)
- HKD 257.88M
- Price to Earnings (P/E)
- 27.6
- Beta
- 2.16
- Next Earnings
- Mar 19, 2027 (Est.)
- EPS Estimate
- 0.22
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving Revenue Growth
The return to meaningful annual revenue growth indicates improving commercial traction and broader product contribution. If sustained, a stronger top line can provide operating leverage, support continued investment in the oncology pipeline, and improve the company’s ability to convert development efforts into future earnings.
Narrowing Cash Burn
The substantial reduction in operating and free cash flow losses shows better cash discipline and improving financial momentum. Although the company remains cash consuming, continued progress would extend funding flexibility, reduce pressure on future capital needs, and support development activity over the next several quarters.
Low And Improving Leverage
Low and declining leverage gives the company greater balance-sheet flexibility while it advances its clinical-stage pipeline. Limited debt burden reduces financing strain relative to a more highly leveraged structure and leaves more capacity to manage ongoing development spending, despite continuing losses.
Bears Say
Persistent Deep Losses
Persistent operating and net losses show that the current business has not yet achieved an earnings model capable of funding itself. Continued deficits can erode capital, constrain strategic flexibility, and make future profitability dependent on successful pipeline development and meaningful revenue scaling.
Negative Free Cash Flow
Ongoing negative free cash flow means operations and development remain dependent on existing capital rather than internally generated funds. This reduces financial resilience over time and increases the importance of improving commercialization, controlling spending, or securing additional funding to sustain the pipeline.
Declining Gross Margin
The sharp gross-margin decline indicates that revenue growth is currently accompanied by weaker economics at the gross-profit level. If the pressure persists, more revenue will be required to absorb research and operating costs, delaying the path to sustainable profitability and limiting operating leverage.
Antengene Corporation Limited News
6996 FAQ
What was Antengene Corporation Limited’s price range in the past 12 months?
What is Antengene Corporation Limited’s market cap?
When is Antengene Corporation Limited’s upcoming earnings report date?
How were Antengene Corporation Limited’s earnings last quarter?
Is Antengene Corporation Limited overvalued?
Does Antengene Corporation Limited pay dividends?
What is Antengene Corporation Limited’s EPS estimate?
How many shares outstanding does Antengene Corporation Limited have?
What happened to Antengene Corporation Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Antengene Corporation Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Antengene Corporation Limited
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jay Mei
- Employees
- 122
- Website
- www.antengene.com
- Address
- Zhongshan SOHO Plaza, Shanghai, SH, 200051, CN
Antengene Corporation Limited (6996) Earnings & Revenues
6996 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |








